Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug
The checkpoint frenzy in the immuno-oncology sphere has largely focused on blocking the ligand-receptor duo of PD-L1 and PD-1, which cancer cells use to shield …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
